Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023–2024

AIM: The "Real-World Multicenter Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes in China" (iCaReMe China) aims to generate contemporary evidence in Chinese type 2 diabetes mellitus (T2DM) patients. MATERIALS AND METHODS: This is a prospective, observational, multicentric registry study with 19 000 subjects from 110 hospitals recruited in China. Adults diagnosed with T2D and/or hypertension (HTN) (combined chronic kidney disease [CKD]), and/or heart failure (HF) and/or CKD were included. Data were collected every 6 months. RESULTS: In this article, we reported the findings from the baseline T2DM cohort, comprising 9000 patients recruited from 60 hospitals. The mean HbA1c level was 8.5 ± 2.2%, with 29.0% of them achieving the target HbA1c goal of <7.0%. The average blood pressure was 131/81 mmHg, with merely 27.8% reaching the target goal of blood pressure below 130/80 mmHg. The mean concentration of low-density lipoprotein cholesterol (LDL-C) was 2.8 ± 1.0 mmol/L, with 43.0% of the patients achieving an LDL-C level below 2.6 mmol/L. Only 5.0% of the patients achieved all three control targets for HbA1c, blood pressure and LDL-C. CONCLUSION: The registry demonstrated suboptimal control rates for cardiovascular risk factors among Chinese T2DM patients, underscoring the imperative need for implementing guideline-directed management.